Skip to main content
. 2019 Mar 12;116(13):6292–6297. doi: 10.1073/pnas.1804000116

Fig. 2.

Fig. 2.

Antitumor activity of aspirin is resolvin-receptor dependent. WRW4 (1 mg/kg/d) and/or aspirin (30 mg/kg/d) with primary LLC (A) or spontaneous MMTV-PyMT (B) tumor growth. Values are mean ± SEM. For MMTV-PyMT mice, tumor volume represents the sum tumor volume of all visible tumors per mouse. n = 5–10 mice/group throughout. The two-tailed Student t test was used for final tumor measurements. *P < 0.05, aspirin vs. control; aspirin vs. aspirin + WRW4. (C) Aspirin (dashed lines) or control (solid lines) with LLC tumor growth in ALX/FPR2 KO mice (red lines) compared with WT mice (blue lines). Treatment was initiated once tumors reached 100–200 mm3. *P < 0.05 vs. WT control; n.s., not significant. (D) WRW4 and aspirin with primary LLC tumor resection and subsequent metastasis. Lung weights (g) and images are representative of lung metastases for each treatment group on day 14 after LLC tumor resection. *P < 0.05, aspirin vs. control; **P < 0.01, aspirin vs. aspirin + WRW4.